Peritoneal pharmacokinetics of cefepime in laparotomy patients with inflammatory bowel disease, and dosage considerations for surgical intra-abdominal infections based on pharmacodynamic assessment

Journal of Infection and Chemotherapy

Volumn 14, Issue 2, 2008, Pages 110-116

  Higuchi, Kazuko ^a,b   Ikawa, Kazuro ^a   Ikeda, Kayo ^a   Ohge, Hiroki ^a   Sueda, Taijiro ^a   Houchi, Hitoshi ^b   Morikawa, Norifumi ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cefepime; Peritoneal fluid; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CEFEPIME;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTEROIDES; BACTEROIDES CACCAE; BACTEROIDES DISTASONIS; BACTEROIDES FRAGILIS; BACTEROIDES OVATUS; BACTEROIDES STERCORIS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES UNIFORMIS; BACTEROIDES VULGATUS; BLOOD SAMPLING; CLINICAL ARTICLE; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG PENETRATION; DRUG PERITONEAL FLUID LEVEL; ENTERITIS; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HUMAN; INFECTION PREVENTION; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LAPAROTOMY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PERITONEAL FLUID; PHARMACODYNAMICS; PREOPERATIVE TREATMENT; PSEUDOMONAS AERUGINOSA; SIMULATION; SURGICAL INFECTION; SURGICAL PATIENT; TREATMENT OUTCOME; ULCERATIVE COLITIS; VENOUS BLOOD;

EID: 43049135181     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-007-0584-x     Document Type: Article

References (20)

1. J.S. Solomkin J.E. Mazuski E.J. Baron R.G. Sawyer A.B. Nathens J.T. DiPiro Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections Clin Infect Dis 37 2003 997 1005 10.1086/378702
2. P. Van der Auwera P.J. Santella Pharmacokinetics of cefepime: a review J Antimicrob Chemother 32 SupplB 1993 103 115
3. J.D. Turnidge The pharmacodynamics of beta-lactams Clin Infect Dis 27 1998 10 22 10.1086/514622
4. W.A. Craig Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and line-zolid Infect Dis Clin North Am 17 2003 479 501 10.1016/S0891-5520(03)00065-5
5. D.E. Burmaster P.D. Anderson Principles of good practice for the use of Monte Carlo techniques in human health and ecological risk assessments Risk Anal 14 1994 477 481 10.1111/j.1539-6924.1994.tb00265.x
6. G.L. Drusano S.L. Preston C. Hardalo R. Hare C. Banfield D. Andes Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint Antimicrob Agents Chemother 45 2001 13 22 10.1128/AAC.45.1.13-22.2001
7. J.W. Mouton M.N. Dudley O. Cars H. Derendorf G.L. Drusano Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update J Antimicrob Chemother 55 2005 601 607 10.1093/jac/dki079
8. W.A. Craig Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins Diagn Microbiol Infect Dis 22 1995 89 96 10.1016/0732-8893(95)00053-D
9. G.L. Drusano Prevention of resistance: a goal for dose selection for antimicrobial agents Clin Infect Dis 36 Suppl1 2003 S42 S50 10.1086/344653
10. J. Cronqvist I. Nilsson-Ehle B. Oqvist S.R. Norrby Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment Antimicrob Agents Chemother 36 1992 2676 2680
11. H. Elkhaili L. Linger H. Monteil F. Jehl High-performance liquid chromatographic assay for cefepime in serum J Chromatogr B Biomed Sci Appl 690 1997 181 188 10.1016/S0378-4347(96)00406-9
12. K. Yamaoka Y. Tanigawara T. Nakagawa T. Uno A pharmacokinetic analysis program (multi) for microcomputer J Pharmacobiodyn 4 1981 879 885
13. N. Shinagawa I. Mizuno K. Hirata T. Katsuramaki T. Mizukuchi Y. Ushijima Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents: special references to bacteria isolated between April 2005 and March 2006 Jpn J Antibiot 60 2007 59 97
14. M.P. Okamoto A. Chin M.A. Gill A.E. Yellin T.V. Berne P.N. Heseltine Analysis of cefepime tissue penetration into human appendix Pharmacotherapy 11 1991 353 358
15. A. Van Gossum M. Quenon M. Van Gossum A. Herchuelz J.P. Thys Penetration of cefoperazone into ascites Eur J Clin Pharmacol 37 1989 577 580
16. G. Benoni E. Arosio M.G. Raimondi P. Pancera A. Lechi G.P. Velo Pharmacokinetics of ceftazidime and ceftriaxone and their penetration into the ascitic fluid J Antimicrob Chemother 16 1985 267 273 10.1093/jac/16.2.267
17. S.L. Buijk I.C. Gyssens J.W. Mouton A. Van Vliet H.A. Verbrugh H.A. Bruining Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections J Antimicrob Chemother 49 2002 121 128 10.1093/jac/49.1.121
18. M. el Touny M. el Guinaidy M. Abdel Bary L. Osman M.S. Sabbour Pharmacokinetics of cefodizime in patients with liver cirrhosis and ascites Chemotherapy 38 1992 201 205 10.1159/000239001
19. P. Liu M. Muller H. Derendorf Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations Int J Antimicrob Agents 19 2002 285 290 10.1016/S0924-8579(02)00024-9
20. F. Rossi F. Baquero P.R. Hsueh D.L. Paterson G.V. Bochicchio T.A. Snyder In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends) J Antimicrob Chemother 58 2006 205 210 10.1093/jac/dkl199